Skip to content
EntityQ3494619· pop 9· linked from 401 articles

seliciclib

Sign in to save

Also known as (R)-roscovitine, CYC-202, CYC202, R-roscovitine, roscovitine, (2R)-2-{[6-(benzylamino)-9-(1-methylethyl)-9H-purin-2-yl]amino}butan-1-ol, 2-(R)-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine, (2R)-2-((9-(1-methylethyl)-6-((phenylmethyl)amino)-9H-purin-2-yl)amino)-1-butanol

Seliciclib (roscovitine or CYC202) is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that inhibit multiple enzyme targets including CDK2, CDK7 and CDK9, which alter the growth phase or state within the cell cycle of treated cells. Seliciclib is being developed by Cyclacel.

Wikidata facts

Mass
354.217
Show 4 more facts
chemical formula
C₁₉H₂₆N₆O
canonical SMILES
CCC(CO)NC1=NC2=C(C(=N1)NCC3=CC=CC=C3)N=CN2C(C)C
isomeric SMILES
CC[C@H](CO)NC1=NC2=C(C(=N1)NCC3=CC=CC=C3)N=CN2C(C)C
World Health Organisation international non-proprietary name
seliciclib
Sources (2)

via Wikidata · CC0

~4 min read

Article

9 sections
Contents
  • Clinical trials and lab tests
  • Cancer treatment
  • Immunological disorders
  • Neurological therapies
  • Antiviral effect
  • Ovum production
  • Renal hypertrophy
  • Side effects
  • References

{{chembox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 377431079 | ImageFile = Seliciclib structure.svg | ImageClass = skin-invert-image | PIN = (2R)-2-{[6-(Benzylamino)-9-(propan-2-yl)-9H-purin-2-yl]amino}butan-1-ol | OtherNames = Roscovitine; CYC202

| Section1=

Available in 9 languages

via Wikidata sitelinks · CC0

Connections

Categories